Back

Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure

31 August 2026 (12:20 - 12:30)
Organised by: Logo
Congress Presentation Part of: Transforming heart failure with next-generation therapies and mechanisms Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Carmen Basic

Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg (Sweden)

4 More presentations in this session

Presentation thumbnail
Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy
Professor W. Ou (CN)
Abstract
Presentation thumbnail
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
Doctor R. Xiao (Chongqing, CN)
Abstract
Presentation thumbnail
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
Doctor F. Cappelli (Florence, IT)
Abstract
Presentation thumbnail
Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart
Doctor Y. Wang (CN)
Abstract

Access the full session

Session thumbnail
Transforming heart failure with next-generation therapies and mechanisms

The Event

Event poster

ESC Congress 2026

31 August 2026 12:20 CET
You may be interested in
thumbnail
Congress Presentation
Optimizing aldosterone receptor antagonist therapy by sodium zirconium cyclosilicate in heart failure - OPRA-HF trial
31 August 2024
thumbnail
Congress Presentation
Mineralocorticoid receptor antagonists after acute myocardial infarction in patients with mild to moderately reduced ejection fraction
22 May 2023
thumbnail
Congress Presentation
Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase
19 May 2025
thumbnail
Congress Presentation
Meta-analysis on the role of potassium binders in optimization of guideline-directed medical therapy and safety outcomes in patients with heart failure
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources